Results 101 to 110 of about 18,310 (204)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS

Научно-практическая ревматология, 2016
Despite major advances in the management of rheumatoid arthritis (RA), whicare associated with the development of new methods for its early diagnosis, the clinical introduction of a wide range of innovative medications and particularly the improvement of
E. L. Nasonov
doaj  

Clinical Management of Antirheumatic Drug Exposure During Therapeutic Plasma Exchange. [PDF]

Clin Rev Allergy Immunol
Ding Z, Li J, Zhong X.
europepmc   +1 more source

Long-term longitudinal changes in bone matrix and turnover markers in rheumatoid arthritis: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Yamashita Y, Maeda K, Maeda K, Okabe H, Hadano Y, Otani T, Saito M.   +6 more
europepmc   +1 more source

Tripterygium Glycoside Tablets Combined With Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Treating Rheumatoid Arthritis: Protocol for a Prospective, Multicenter, Open-Label Randomized Controlled Trial. [PDF]

JMIR Res Protoc
Lv L, Wang T, Lv J, Liu C, Zhao L, Zhou Y.   +5 more
europepmc   +1 more source

Interpretable Machine Learning Framework for Predicting Major Adverse Cardiovascular Events in Rheumatoid Arthritis Using Electronic Health Records: Multicenter Cohort Study. [PDF]

JMIR Form Res
Chiang WC, Lin GL, Chang YS, Liu YC, Huang CW, Nguyen PA, Hsu JC, Liou DM, Yang HC.   +8 more
europepmc   +1 more source

Real-World Outcomes of Baricitinib Monotherapy Versus csDMARD Combination Therapy in Rheumatoid Arthritis: A SingleCenter Retrospective Analysis of Efficacy, Safety, and Drug Retention

The Turkish Journal of Gastroenterology
Background/Aims: This study compared the effectiveness, adverse effects (AEs), and drug retention rates of baricitinib (BARI) monotherapy versus combination therapy in rheumatoid arthritis (RA) patients.
Mete Kara, Gülay Alp, Haluk Cinakli
doaj  

Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate. [PDF]

Ther Adv Musculoskelet Dis
Yoon J, Han M, Song JJ, Lee SW, Jung I, Park YB.   +5 more
europepmc   +1 more source

Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses. [PDF]

RMD Open
van Esveld L, Dikkenberg MVD, Luurssen-Masurel N, de Jong P, Kok MR, Bosch T, Hackert MQN, Weel-Koenders A, Lopes Barreto D, Kuijper TM.   +9 more
europepmc   +1 more source

Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users. [PDF]

BMC Infect Dis
Kuo MH, Tseng CW, Huang CW, Tseng KC, Lu MC, Tung CH, Chen NT, Huang KY, Lai NS.   +8 more
europepmc   +1 more source

Long-Term Effects of Rheumatoid Arthritis Treatments on Bone Mineral Density: 8-Year-Follow-Up Data from Real-World Practice. [PDF]

J Clin Med
Barbaro LE, Bustamente L, Evenor L, Villain A, Vall A, Fabre R, Bailly L, Breuil V, Pradier C, Roux C.   +9 more
europepmc   +1 more source